Featured Research

from universities, journals, and other organizations

More action needed to prevent stomach problems in NSAID users, despite recent progress

Date:
June 17, 2010
Source:
Wiley-Blackwell
Summary:
Four out of ten high-risk patients prescribed nonsteroidal anti-inflammatory drugs also received appropriate measures to prevent upper-gastrointestinal problems, but the remainder did not receive adequate protection. The study covered more than 50,000 patients aged 50 plus, analyzing prescribing trends over an 11-year period.

Four out of ten high-risk patients prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) also received appropriate measures to prevent upper-gastrointestinal (UGI) problems, but the remainder did not receive adequate protection, according to a study in the June issue of Alimentary Pharmacology and Therapeutics.

Although the number of patients receiving preventative strategies increased five-fold over the 11-year period studied by researchers in The Netherlands, greater steps need to be taken to protect patients who face a high risk of side effects.

"NSAIDs are among the world's most frequently prescribed drugs for arthritis and inflammatory conditions, but their use can quadruple the risk of upper gastrointestinal problems" explains lead researcher Dr Vera Valkhoff from the Erasmus University Medical Centre in Rotterdam.

"These can range from mild symptoms like indigestion to more serious conditions like bleeding, perforation or obstructions, which can lead to hospital admissions or, in some cases, death.

"Preventative strategies include using a COX inhibitor NSAID instead of a nonselective NSAID and combining NSAIDs with gastroprotective agents. However international studies suggest that as many as three-quarters of high- risk patients are not receiving adequate protection from the side effects of NSAIDs."

The research team looked at the records of 50,126 NSAID users aged 50 or over from the Integrated Primary Care Database, using the latest figures available (1996 to 2006).

This showed that just under seven per cent of high-risk patients had been correctly prescribed preventative strategies in 1996, but by 2006 this had risen to over 39 per cent. However, the latest figure was nine per cent higher for patients who had a medical history of UGI problems.

A correct prescription was defined as a patient receiving a preventative strategy if they were defined as high risk because of a history of UGI bleeding/ulceration, being 65 or over or using anticoagulants, aspirin or corticosteroids. This category also included low-risk patients who were not receiving a preventative strategy, as there is no indication that this is necessary in such cases.

Under-prescription was defined as a high-risk patient not receiving a strategy and over prescription as a low-risk patient receiving a strategy.

Key findings of the study include:

  • Just over 43 per cent of NSAID users were defined as high-risk because of at least one risk factor. Being aged 65 or over was the most frequent risk factor (40 per cent) followed by use of anticoagulants (nine per cent) and having diabetes mellitus (eight per cent).
  • The researchers found that the remaining 57 per cent of the study population had no NSAID-related upper-gastrointestinal (UGI) risk factors and were therefore deemed as low risk.
  • Correct prescriptions among high-risk users rose from seven per cent in 1996 to 39 per cent in 2006. But the number of low-risk users who received unnecessary preventative strategies also rose, from three per cent in 1996 to 12 per cent in 2006.
  • Preventative strategies for patients with a medical history of UGI events rose from 27 per cent in 1996 to 48 per cent in 2006. When older age was factored in (75 plus) these figures rose from nine per cent in 1996 to 49 per cent in 2006.
  • High-risk patients had a higher average age than low-risk patients (73 versus 55.6 years) and were more likely to be female than male (60 per cent versus 54 per cent).

"Our study shows that, although considerable improvements have been made in prescribing preventative strategies for people taking NSAIDs, the majority of high-risk users, including those with a history of UGI events, are not receiving adequate protection from side effects.

"We hope that our study will draw attention to the international need for patient risk to be evaluated and appropriate action taken to ensure that NSAID use does not lead to UGI problems."



Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. V. E. Valkhoff, E. M. Van Soest, M. C. J. M. Sturkenboom, E. J. Kuipers. Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Alimentary Pharmacology & Therapeutics, 2010; 31 (11): 1218 DOI: 10.1111/j.1365-2036.2010.04281.x

Cite This Page:

Wiley-Blackwell. "More action needed to prevent stomach problems in NSAID users, despite recent progress." ScienceDaily. ScienceDaily, 17 June 2010. <www.sciencedaily.com/releases/2010/06/100617102414.htm>.
Wiley-Blackwell. (2010, June 17). More action needed to prevent stomach problems in NSAID users, despite recent progress. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/06/100617102414.htm
Wiley-Blackwell. "More action needed to prevent stomach problems in NSAID users, despite recent progress." ScienceDaily. www.sciencedaily.com/releases/2010/06/100617102414.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins